Your browser doesn't support javascript.
loading
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
Hochhaus, A; Saglio, G; Hughes, T P; Larson, R A; Kim, D-W; Issaragrisil, S; le Coutre, P D; Etienne, G; Dorlhiac-Llacer, P E; Clark, R E; Flinn, I W; Nakamae, H; Donohue, B; Deng, W; Dalal, D; Menssen, H D; Kantarjian, H M.
Afiliación
  • Hochhaus A; Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena, Germany.
  • Saglio G; Division of Internal Medicine & Hematology, University of Turin, Orbassano, Italy.
  • Hughes TP; South Australian Health and Medical Research Institute (SAHMRI), University of Adelaide, SA Pathology, Adelaide, South Australia, Australia.
  • Larson RA; Department of Medicine, The University of Chicago, Chicago, IL, USA.
  • Kim DW; Leukemia Research Institute, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
  • Issaragrisil S; Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • le Coutre PD; Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Etienne G; Centre Régional de Lutte Contre le Cancer de Bordeaux et du Sud-Ouest, Institut Bergonié, Département d'Oncologie Médicale, Bordeaux, France.
  • Dorlhiac-Llacer PE; Hospital das Clinicas FMUSP, São Paulo, Brazil.
  • Clark RE; Royal Liverpool University Hospital, Liverpool, UK.
  • Flinn IW; Sarah Cannon Research Institute, Nashville, TN, USA.
  • Nakamae H; Department of Hematology, Osaka City University, Osaka, Japan.
  • Donohue B; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Deng W; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Dalal D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Menssen HD; Novartis Pharma AG, Basel, Switzerland.
  • Kantarjian HM; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 30(5): 1044-54, 2016 05.
Article en En | MEDLINE | ID: mdl-26837842
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide de Fase Crónica / Mesilato de Imatinib Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirimidinas / Leucemia Mielógena Crónica BCR-ABL Positiva / Leucemia Mieloide de Fase Crónica / Mesilato de Imatinib Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leukemia Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania